| Literature DB >> 27543602 |
Cheng S Jin1, Hironobu Wada2, Takashi Anayama2, Patrick Z McVeigh3, Hsin Pei Hu2, Kentaro Hirohashi2, Takahiro Nakajima2, Tatsuya Kato2, Shaf Keshavjee2, David Hwang4, Brian C Wilson5, Gang Zheng6, Kazuhiro Yasufuku7.
Abstract
Early detection and efficient treatment modality of early-stage peripheral lung cancer is essential. Current nonsurgical treatments for peripheral lung cancer show critical limitations associated with various complications, requiring alternative minimally invasive therapeutics. Porphysome nanoparticle-enabled fluorescence-guided transbronchial photothermal therapy (PTT) of peripheral lung cancer was developed and demonstrated in preclinical animal models. Systemically administered porphysomes accumulated in lung tumors with significantly enhanced disease-to-normal tissue contrast, as confirmed in three subtypes of orthotopic human lung cancer xenografts (A549, H460, and H520) in mice and in an orthotopic VX2 tumor in rabbits. An in-house prototype fluorescence bronchoscope demonstrated the capability of porphysomes for in vivo imaging of lung tumors in the mucosal/submucosal layers, providing real-time fluorescence guidance for transbronchial PTT. Porphysomes also enhanced the efficacy of transbronchial PTT significantly and resulted in selective and efficient tumor tissue ablation in the rabbit model. A clinically used cylindrical diffuser fiber successfully achieved tumor-specific thermal ablation, showing promising evidence for the clinical translation of this novel platform to impact upon nonsurgical treatment of early-stage peripheral lung cancer. Cancer Res; 76(19); 5870-80. ©2016 AACR. ©2016 American Association for Cancer Research.Entities:
Mesh:
Year: 2016 PMID: 27543602 PMCID: PMC5050138 DOI: 10.1158/0008-5472.CAN-15-3196
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701